in Newswire February 22, 2019

Amgen, Teva Sued Over Allegedly Anticompetitive Practices Relating to Sensipar Pricing

by Erin Gilmore

Last Updated on February 22, 2019

Ufcw Local 1500 Welfare Fund v. Amgen Inc. et al

Filed: February 21, 2019 § 1:19cv369

Amgen Inc., Teva Pharmaceuticals USA, Inc. and three Teva subsidiaries have been named in a proposed class action in which they’re accused of entering into an unlawful, anticompetitive agreement that led consumers to pay inflated prices for Sensipar.

Last Updated on February 22, 2019 — 4:02 PM

Erin Gilmore

erin@classaction.org

Erin works primarily on ClassAction.org’s newswire, reporting on cases as they happen. She is an honest writer, a faithful friend, and a mediocre bassist.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.